LUCD – lucid diagnostics inc. (US:NASDAQ)
Stock Stats
News
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its price target lowered by analysts at Cantor Fitzgerald from $3.00 to $2.00. They now have an "overweight" rating on the stock.
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $3.00 price target on the stock.
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $2.50 price target on the stock.
Form 8-K Lucid Diagnostics Inc. For: Nov 12
Form 8-K Lucid Diagnostics Inc. For: Nov 13
Form 10-Q Lucid Diagnostics Inc. For: Sep 30
Form 8-K Lucid Diagnostics Inc. For: Nov 08
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.